1.Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study.
Huai ZHANG ; Rafael S RIOS ; Jerome BOURSIER ; Rodolphe ANTY ; Wah-Kheong CHAN ; Jacob GEORGE ; Yusuf YILMAZ ; Vincent Wai-Sun WONG ; Jiangao FAN ; Jean-François DUFOUR ; George PAPATHEODORIDIS ; Li CHEN ; Jörn M SCHATTENBERG ; Junping SHI ; Liang XU ; Grace Lai-Hung WONG ; Naomi F LANGE ; Margarita PAPATHEODORIDI ; Yuqiang MI ; Yujie ZHOU ; Christopher D BYRNE ; Giovanni TARGHER ; Gong FENG ; Minghua ZHENG
Chinese Medical Journal 2023;136(3):341-350
BACKGROUND:
Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and possible sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may be useful in diagnosing NASH, but results across studies have been inconsistent. We aimed to identify the utility of CK-18 M30 concentrations as an alternative to liver biopsy for non-invasive identification of NASH.
METHODS:
Individual data were collected from 14 registry centers on patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD), and in all patients, circulating CK-18 M30 levels were measured. Individuals with a NAFLD activity score (NAS) ≥5 with a score of ≥1 for each of steatosis, ballooning, and lobular inflammation were diagnosed as having definite NASH; individuals with a NAS ≤2 and no fibrosis were diagnosed as having non-alcoholic fatty liver (NAFL).
RESULTS:
A total of 2571 participants were screened, and 1008 (153 with NAFL and 855 with NASH) were finally enrolled. Median CK-18 M30 levels were higher in patients with NASH than in those with NAFL (mean difference 177 U/L; standardized mean difference [SMD]: 0.87 [0.69-1.04]). There was an interaction between CK-18 M30 levels and serum alanine aminotransferase, body mass index (BMI), and hypertension ( P < 0.001, P = 0.026 and P = 0.049, respectively). CK-18 M30 levels were positively associated with histological NAS in most centers. The area under the receiver operating characteristics (AUROC) for NASH was 0.750 (95% confidence intervals: 0.714-0.787), and CK-18 M30 at Youden's index maximum was 275.7 U/L. Both sensitivity (55% [52%-59%]) and positive predictive value (59%) were not ideal.
CONCLUSION
This large multicenter registry study shows that CK-18 M30 measurement in isolation is of limited value for non-invasively diagnosing NASH.
Humans
;
Non-alcoholic Fatty Liver Disease/diagnosis*
;
Keratin-18
;
Biomarkers
;
Biopsy
;
Hepatocytes/pathology*
;
Apoptosis
;
Liver/pathology*
2.Nonalcoholic fatty liver disease in the elderly.
Chinese Journal of Hepatology 2016;24(2):92-95
Along with the aging process, the spectrum of liver disease changes greatly. Nonalcoholic fatty liver disease (NAFLD) in elderly people lead to low liver function and is also the major cause of extrahepatic diseases, such as cardiovascular disease and malignant tumor. This review provides an overview of the morphological structure and function of the liver in aged people, and discusses the characteristics of weakness, malnutrition and limited movement in the elderly, as well as the current status of multiple diseases and multiple drug use. Finally, this article puts forward some appropriate regimens for the diagnosis and treatment of NAFLD in elderly people to provide a reference for clinical practice.
Aged
;
Cardiovascular Diseases
;
Humans
;
Liver
;
pathology
;
Malnutrition
;
Neoplasms
;
Non-alcoholic Fatty Liver Disease
;
diagnosis
;
pathology
;
therapy
;
Risk Factors
3.Managing non-alcoholic fatty liver disease.
Jing Hieng NGU ; George Boon Bee GOH ; Zhongxian POH ; Roy SOETIKNO
Singapore medical journal 2016;57(7):368-371
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing rapidly with the obesity and diabetes mellitus epidemics. It is rapidly becoming the most common cause of liver disease worldwide. NAFLD can progress to serious complications such as cirrhosis, hepatocellular carcinoma and death. Therefore, it is important to recognise this condition so that early intervention can be implemented. Lifestyle modifications and strict control of metabolic risk factors are the mainstay of treatment. As disease progression is slow in the majority of NAFLD patients, most can be managed well by primary care physicians. NAFLD patients with advanced liver fibrosis should be referred to specialist care for further assessment.
Carcinoma, Hepatocellular
;
pathology
;
Diet
;
Disease Progression
;
Humans
;
Life Style
;
Liver
;
pathology
;
Liver Cirrhosis
;
pathology
;
Liver Neoplasms
;
pathology
;
Metabolic Syndrome
;
complications
;
Non-alcoholic Fatty Liver Disease
;
diagnosis
;
therapy
;
Obesity
;
complications
;
Prevalence
;
Risk Factors
;
Treatment Outcome
4.Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
Hyunwoo OH ; Dae Won JUN ; Waqar K SAEED ; Mindie H NGUYEN
Clinical and Molecular Hepatology 2016;22(3):327-335
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a "hot potato" for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD.
Biomarkers/analysis
;
Chenodeoxycholic Acid/analogs & derivatives/therapeutic use
;
Clinical Trials as Topic
;
Fatty Liver/diagnosis
;
Fibrosis
;
Humans
;
Liver/diagnostic imaging/pathology
;
Magnetic Resonance Imaging
;
Non-alcoholic Fatty Liver Disease/*diagnosis/drug therapy
;
Tomography, X-Ray Computed
;
Ultrasonography
;
Vitamin E/therapeutic use
5.A practical clinical approach to liver fibrosis.
Rahul KUMAR ; Eng Kiong TEO ; Choon How HOW ; Teck Yee WONG ; Tiing Leong ANG
Singapore medical journal 2018;59(12):628-633
Liver fibrosis is a slow, insidious process involving accumulation of extracellular matrix protein in the liver. The stage of liver fibrosis in chronic liver disease (CLD) determines overall morbidity and mortality; the higher the stage, the worse the prognosis. Noninvasive composite scores can be used to determine whether patients with CLD have significant or advanced fibrosis. Patients with low composite scores can be safely followed up in primary care with periodic reassessment. Those with higher scores should be referred to a specialist. As the epidemic of diabetes mellitus, obesity and non-alcoholic fatty liver diseases is rising, CLD is becoming more prevalent. Easy-to-use fibrosis assessment composite scores can identify patients with minimal or advanced fibrosis, and should be an integral part of decision-making. Patients with cirrhosis, high composite scores, chronic hepatitis B with elevated alanine aminotransferase and aspartate aminotransferase, or deranged liver panel of uncertain aetiology should be referred to a specialist.
Alanine Transaminase
;
blood
;
Aspartate Aminotransferases
;
blood
;
Decision Making
;
End Stage Liver Disease
;
complications
;
diagnosis
;
therapy
;
Hepatitis B
;
complications
;
Humans
;
Liver
;
pathology
;
Liver Cirrhosis
;
complications
;
diagnosis
;
therapy
;
Non-alcoholic Fatty Liver Disease
;
complications
;
diagnosis
;
therapy
;
Prognosis
;
Referral and Consultation
;
Treatment Outcome
6.Clinical Features of Non-alcoholic Fatty Liver Disease in Cryptogenic Hepatocellular Carcinoma.
Min Young RIM ; Oh Sang KWON ; Minsu HA ; Ju Seung KIM ; Kwang Il KO ; Dong Kyu KIM ; Pil Kyu JANG ; Jung Yoon HAN ; Pyung Hwa PARK ; Young Kul JUNG ; Duck Joo CHOI ; Yun Soo KIM ; Ju Hyun KIM
The Korean Journal of Gastroenterology 2014;63(5):292-298
BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) may be one of the important causes of cryptogenic hepatocellular carcinoma (HCC). The aim of this study was to evaluate whether patients with cryptogenic HCC share clinical features similar to that of NAFLD. METHODS: Cryptogenic HCC was defined as HCC that occurs in patients with the following conditions: HBsAg(-), anti-HCV(-), and alcohol ingestion of less than 20 g/day. All patients diagnosed with cryptogenic HCC from 2005 to 2012 (cryptogenic HCC group), and all patients diagnosed with HBV associated HCC between 2008 and 2012 (HBV-HCC group) were enrolled in the present study. Clinical features, BMI, lipid profiles, presence of diabetes mellitus, hypertension, and metabolic syndrome were compared between the two groups. RESULTS: Cryptogenic HCC group was composed of 35 patients (19 males and 16 females) with a mean age of 70+/-11 years. HBV-HCC group was composed of 406 patients (318 males and 88 females) with a mean age of 56+/-7 years. Patients in the cryptogenic HCC group were older (p=0.001) and female dominant (p=0.042) than those in the HBV-HCC group. There were no differences in the laboratory test results including lipid profiles and Child-Turcotte-Pugh class between the two groups. Patients in the cryptogenic HCC group had higher prevalence of diabetes (37% vs. 17%, p=0.015), hypertension (49% vs. 27%, p=0.051), metabolic syndrome (37% vs. 16%, p=0.001), and higher BMI (25.3 kg/m2 vs. 24.1 kg/m2, p=0.042) than those in the HBV-HCC group. The tumor stage was more advanced (stage III and IV) at diagnosis in the cryptogenic HCC group than in the HBV-HCC group (60% vs. 37%, p=0.007). CONCLUSIONS: Cryptogenic HCC has clinical features similar to that of NAFLD and is diagnosed at a more advanced tumor stage.
Age Factors
;
Aged
;
Body Mass Index
;
Carcinoma, Hepatocellular/*diagnosis/etiology/pathology
;
Diabetes Complications
;
Diabetes Mellitus/pathology
;
Female
;
Hepatitis B/complications
;
Humans
;
Hypertension/complications
;
Lipids/blood
;
Liver Neoplasms/*diagnosis/etiology/pathology
;
Male
;
Metabolic Syndrome X/complications
;
Middle Aged
;
Neoplasm Staging
;
Non-alcoholic Fatty Liver Disease/*diagnosis/pathology
;
Risk Factors
;
Severity of Illness Index
;
Sex Factors
7.Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis.
Mei YANG ; Yisi LIU ; Guangde ZHOU ; Xiaodong GUO ; Saiying ZOU ; Shuhong LIU ; Lina JIANG ; Yuan LIU ; Li ZHU ; Chaonan GUO ; Jingmin ZHAO
Chinese Journal of Hepatology 2016;24(2):96-101
OBJECTIVETo investigate the correlation of serum osteoprotegerin (OPG) with the progression of nonalcoholic fatty liver disease (NAFLD) and the noninvasive prediction and diagnosis of nonalcoholic steatohepatitis (NASH).
METHODSA total of 136 patients with NAFLD were enrolled, and their tissue samples for liver biopsy and serum samples obtained at 1 week after liver biopsy were collected; 83 healthy subjects without the symptoms of fatty liver disease proved by ultrasound examination were enrolled as controls. The physiological indicators including height, body weight, and waist circumference were measured, and body mass index was calculated. The biochemical parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST/ALT, alkaline phosphatase, gamma-glutamyl transferase, total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured. Double-antibody sandwich enzyme-linked immunosorbent assay was used to determine the serum level of OPG. The rank sum test, chi-square test, t-test, one-way analysis of variance, Spearman correlation analysis, least significant difference test, and receiver operating characteristic (ROC) curve were applied for statistical analysis of various data.
RESULTSSerum OPG level was correlated with AST and TG (P < 0.05), and was highly correlated with hepatocyte fatty degeneration, ballooning degeneration, intralobular inflammation, portal inflammation, and fibrosis degree (P < 0.01). With the increasing NAFLD activity score (NAS), serum OPG level decreased, and there was a highly negative correlation between them (r = -0.928, P < 0.01). Serum OPG level was significantly lower in NASH patients than non-NASH patients. The area under the ROC curve of serum OPG level was 0.963, and according to the Youden index, its optimal sensitivity and specificity were 96.1% and 97.4%, respectively, at an optimal cut-off value of 242.96 ng/L, which suggested a high diagnostic power.
CONCLUSIONIn NASH patients, serum OPG level decreases significantly. Serum OPG level can be used as an independent predictive factor to evaluate NASH and its severity, as well as a noninvasive diagnostic index for NASH.
Alanine Transaminase ; blood ; Alkaline Phosphatase ; blood ; Aspartate Aminotransferases ; blood ; Biopsy ; Body Mass Index ; Case-Control Studies ; Cholesterol ; blood ; Disease Progression ; Enzyme-Linked Immunosorbent Assay ; Fibrosis ; Humans ; Inflammation ; pathology ; Liver ; pathology ; Non-alcoholic Fatty Liver Disease ; blood ; diagnosis ; Osteoprotegerin ; blood ; ROC Curve ; Triglycerides ; blood ; gamma-Glutamyltransferase ; blood
8.Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
Gi Hyun KIM ; Jung Wha CHUNG ; Jong Ho LEE ; Kyeong Sam OK ; Eun Sun JANG ; Jaihwan KIM ; Cheol Min SHIN ; Young Soo PARK ; Jin Hyeok HWANG ; Sook Hyang JEONG ; Nayoung KIM ; Dong Ho LEE ; Jin Wook KIM
Clinical and Molecular Hepatology 2015;21(4):379-386
BACKGROUND/AIMS: Vitamin E improves the biochemical profiles and liver histology in nonalcoholic steatohepatitis, but the role of vitamin E is not clearly defined in the management of nonalcoholic fatty liver disease (NAFLD) which includes both simple steatosis and steatohepatitis. Co-morbid metabolic syndrome increases the probability of steatohepatitis in NAFLD. In this study, we aimed to determine the short-term effects of vitamin E and off-treatment durability of response in a propensity-score matched cohort of NAFLD patients with metabolic syndrome. METHODS: A retrospective cohort was constructed by retrieving 526 consecutive NAFLD patients from the electronic medical record data warehouse of a tertiary referral hospital in South Korea. Among them, 335 patients (63.7%) had metabolic syndrome and were eligible for vitamin E therapy. In order to assess the effect of vitamin E, propensity score matching was used by matching covariates between control patients (n=250) and patients who received vitamin E (n=85). RESULTS: The PS-matched vitamin E group (n=58) and control group (n=58) exhibited similar baseline metabolic profiles. After 6 months of vitamin E therapy, the mean ALT levels decreased significantly compared to PS-matched control (P<0.01). The changes in metabolic profiles (body weight, lipid and glucose levels) did not differ between control and vitamin E groups during the study period. CONCLUSIONS: Short-term vitamin E treatment significantly reduces ALT levels in NAFLD patients with metabolic syndrome, but metabolic profiles are not affected by vitamin E.
Adult
;
Aged
;
Alanine Transaminase/blood
;
Aspartate Aminotransferases/blood
;
Body Weight
;
Cohort Studies
;
Female
;
Humans
;
Lipoproteins, HDL/blood
;
Lipoproteins, LDL/blood
;
Liver/pathology
;
Male
;
Metabolic Syndrome X/*complications/diagnosis/drug therapy
;
Middle Aged
;
Non-alcoholic Fatty Liver Disease/*complications/diagnosis/*drug therapy
;
Propensity Score
;
Republic of Korea
;
Retrospective Studies
;
Vitamin E/*therapeutic use
9.Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis.
Min Kyoung KANG ; Byeong Hun KANG ; Jong Ho KIM
Yonsei Medical Journal 2015;56(5):1288-1295
PURPOSE: In this study, we aimed to evaluate whether nonalcoholic fatty liver disease (NAFLD) was associated with the presence and morphology of coronary atherosclerotic plaques shown by multidetector computed tomography (MDCT) in asymptomatic subjects without a history of cardiovascular disease. MATERIALS AND METHODS: We retrospectively enrolled 772 consecutive South Korean individuals who had undergone both dualsource 64-slice MDCT coronary angiography and hepatic ultrasonography during general routine health evaluations. The MDCT studies were assessed for the presence, morphology (calcified, mixed, and non-calcified), and severity of coronary plaques. RESULTS: Coronary atherosclerotic plaques were detected in 316 subjects (40.9%) by MDCT, and NAFLD was found in 346 subjects (44.8%) by hepatic ultrasonography. Subjects with NAFLD had higher prevalences of all types of atherosclerotic plaque and non-calcified, mixed, and calcified plaques than the subjects without NAFLD. However, the prevalence of significant stenosis did not differ between groups. After adjusting for age, smoking status, diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome, NAFLD remained a significant predictor for all types of coronary atherosclerotic plaque [odds ratio (OR): 1.48; 95% confidence interval (CI): 1.05-2.08; p=0.025] in binary logistic analysis, as well as for calcified plaques (OR: 1.70; 95% CI: 1.07-2.70; p=0.025) in multinomial regression analysis. CONCLUSION: Our study demonstrated that NAFLD was significantly associated with the presence and the calcified morphology of coronary atherosclerotic plaques detected by MDCT. Further prospective clinical studies are needed to clarify the exact physiopathologic role of NAFLD in coronary atherosclerosis.
Adult
;
Aged
;
Asian Continental Ancestry Group/statistics & numerical data
;
Calcinosis/ethnology/*radiography
;
Case-Control Studies
;
Coronary Angiography/*methods
;
Coronary Artery Disease/ethnology/pathology/*radiography
;
Female
;
Humans
;
Male
;
Middle Aged
;
Multidetector Computed Tomography/*methods
;
Non-alcoholic Fatty Liver Disease/epidemiology/*ultrasonography
;
Odds Ratio
;
Plaque, Atherosclerotic/*diagnosis/epidemiology
;
Prevalence
;
Regression Analysis
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Ultrasonography